Glycomics Market Size, Global Analytical Overview, Key Players, Regional Demand, Trends and Forecast to 2027
Glycomics/ Glycobiology Market size is projected to reach USD 3.7 billion by 2027 from USD 1.8 billion in 2022, at a CAGR of 15.5% during the forecast period of 2022 to 2027 according to a new report by MarketsandMarkets™

According to the new market research report "Glycomics/Glycobiology Market by Product (Enzymes (Glycosidases, Transferases), Instruments (Mass Spectrometry, Chromatography, Arrays), Kits, Carbohydrates, Reagents), Application (Drug Discovery, Diagnostics), End User - Global Forecast to 2027", The glycomics/glycobiology market is projected to reach USD 3.7 Billion by 2027 from USD 1.8 Billion in 2022, at a CAGR of 15.5% during the forecast period.


Browse in-depth TOC on "Glycomics|Glycobiology Market"

376 - Tables

41 - Figures

319 - Pages


Download PDF Brochure:


Key Players:

Key players in the glycomics/glycobiology market are Thermo Fisher Scientific (US), New England Biolabs (US), Merck KGaA (Germany), Promega Corporation (US), Waters Corporation (US), Takara Bio Inc, (Japan), Bio-Techne (US), Agilent Technologies (US), Sumitomo Bakelite Co. Ltd. (Japan), Bruker Corporation (US), Shimadzu Corporation (Japan), Danaher Corporation (US), AMS Bio (UK), Ludger Ltd (UK), Z Biotech, LLC (US), Chemily Glycoscience (US), CD BioGlyco (US), GlycoDiag (France), Kode Biotech Limited (New Zealand), Glyxera GmBH (Germany), Lectenz Bio (US), Glycomix Ltd (UK), IEC Group (Italy), Asparia Glycomics (Spain) and Ray Biotech Life Inc. (US).

Global Glycomics/ Glycobiology Market Size, Share, Trends and Dynamics

Drivers: Emergence of glycans as biomarkers

Glycans play a vital role in biology; alterations in glycans can lead to dangerous consequences, such as congenital disorders, heart diseases, growth defects, and epilepsy. Research has shown that mutation in glycosyltransferases or related enzymes modifies/alters the glycome and can cause over 100 types of human congenital disorders of glycosylation.

Restraints: Extravagant cost of glycobiology products and tools

The high cost of glycobiology products and instruments like reagents, carbohydrates, mass spectrometers, glycan analysis kits, and enzymes pose an obstacle to their adoption. Developing glycobiology tools requires significant investment; stringent rules and regulations make them even more expensive.

Opportunities: Glycomics applications in precision medicine

Precision medicine has grown rapidly in the last few years. Many pharma and biotech companies are investing heavily to develop targeted drugs that can be used for a specific group of patients. Sugars present on the surface of the cells and complex biomolecules are involved in various processes, including cell recognition and communication. These are crucial processes in inflammation, autoimmune disease, and viral & bacterial infections.

Request Sample Pages:

Challenges: Lack of skilled workforce

One of the biggest challenges is the lack of skilled workforce engaged in glycobiology research and conduct the process. This is very time consuming, cost ineffective and risky process. Even the staff who handles the glycobiology products are present in scarce. This factor is a biggest obstacle in the market.

North America is the fastest-growing region of the glycomics/glycobiology market.

North America is estimated to be the fastest-growing segment of the market. The growth of the glycomics/glycobiology market in this region is driven by the presence of prominent market players offering glycomics products, increasing focus on glycomics research and its application in drug development and availability of research infrastructure in the US.

Recent Developments

·         Bruker Corporation (US) acquired the IonSense (US) for expansion of the use of DART Mass spectrometers.

·         GlycoNet (Canada) and BridgeBio Pharma Inc, (US) entered into partnership for developing medicines for treating genetic diseases through glycobiology research.

Speak to Analyst:

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.


Mr. Aashish Mehra

MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA : 1-888-600-6441